{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["118"],"submitter":["Lee DS"],"pubmed_abstract":["<h4>Objectives</h4>To investigate the clinical characteristics of adverse events (AEs) after COVID-19 vaccination in patients in South Korea.<h4>Design</h4>Data from the Korean Disease Control and Prevention Agency on AEs from 4 COVID-19 vaccines, including AZD1222, BNT162b2, JNJ-78436735, and mRNA-1273, from February 26, 2021, to August 21, 2021, were assessed. The epidemiological characteristics, clinical symptoms, severity, complications, and mortality were descriptively analyzed.<h4>Results</h4>Overall, 36.3 million individuals who completed the COVID-19 vaccination doses during the study period were included, and 153,183 AEs were reported. Most AEs occurred after the first dose (80.6%) and within a day (63.2%) after vaccination. Of the AEs, 95.5% were nonsevere cases; however, 4.5% were severe. Most mild AEs showed a similar frequency across all age groups, but major severe AEs and mortality events increased with age.<h4>Conclusions</h4>Although there were differences in the frequency of occurrence, various adverse reactions were confirmed in using all 4 COVID-19 vaccines, even with the BNT162b2 (Pfizer-BioNTech) vaccine. Caution is needed, and further research should be continuously conducted."],"journal":["International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"],"pagination":["173-182"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8904009"],"repository":["biostudies-literature"],"pubmed_title":["Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study."],"pmcid":["PMC8904009"],"pubmed_authors":["Kang HW","Kim JW","Lee KL","Jung YJ","Lee DS"],"additional_accession":[]},"is_claimable":false,"name":"Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.","description":"<h4>Objectives</h4>To investigate the clinical characteristics of adverse events (AEs) after COVID-19 vaccination in patients in South Korea.<h4>Design</h4>Data from the Korean Disease Control and Prevention Agency on AEs from 4 COVID-19 vaccines, including AZD1222, BNT162b2, JNJ-78436735, and mRNA-1273, from February 26, 2021, to August 21, 2021, were assessed. The epidemiological characteristics, clinical symptoms, severity, complications, and mortality were descriptively analyzed.<h4>Results</h4>Overall, 36.3 million individuals who completed the COVID-19 vaccination doses during the study period were included, and 153,183 AEs were reported. Most AEs occurred after the first dose (80.6%) and within a day (63.2%) after vaccination. Of the AEs, 95.5% were nonsevere cases; however, 4.5% were severe. Most mild AEs showed a similar frequency across all age groups, but major severe AEs and mortality events increased with age.<h4>Conclusions</h4>Although there were differences in the frequency of occurrence, various adverse reactions were confirmed in using all 4 COVID-19 vaccines, even with the BNT162b2 (Pfizer-BioNTech) vaccine. Caution is needed, and further research should be continuously conducted.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-29T10:59:50.664Z","creation":"2025-04-06T19:49:52.05Z"},"accession":"S-EPMC8904009","cross_references":{"pubmed":["35276381"],"doi":["10.1016/j.ijid.2022.03.007"]}}